Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study
Arthritis & Rheumatism, 09/03/08

Sundy JS et al. – Pegloticase, administered in multiple doses, was effective in rapidly reducing and maintaining plasma urate levels at ≤6 mg/dl in most patients in whom conventional therapy had been unsuccessful due to lack of response, intolerability, or contraindication.

Methods

Study to assess the efficacy of pegloticase in achieving and maintaining plasma urate levels of <6 mg/dl in gout pts
41 pts randomized to undergo 12-14 wks of treatment with pegloticase: 4 mg every 2 wks, 8 mg every 2 wks, 8 mg every 4 wks, or 12 mg every 4 wks
Plasma uricase activity, plasma urate, and antipegloticase abs were measured, pharmacokinetic parameters were assessed, and AEs were recorded

Results

The mean plasma urate level was reduced to ≤6 mg/dl within 6 h in all dosage groups; sustained in the 8 mg and 12 mg dosage groups
The most effective dosage was 8 mg every 2 wks
In 50-80% pts primary efficacy end point was achieved
Gout flares occurred in 88% of the pts
AEs were unrelated to treatment and were mild or moderate in severity
Infusion-day AEs were the most common reason for study withdrawal
There were no anaphylactic reactions
Antipegloticase ab was associated with reduced circulating half-life of pegloticase in some pts

<< Previous
Practices hit Medicare P4P quality targets, but bonuses still...

Next >>
Decreased expression of caveolin 1 in patients with systemic...